event-free survival

Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-world evidence study

McCann KE, Osman N, Cannon J, Brent L, Wang Y, Tepsick J, Mandora PV, Miller V, Martin N, Kaklamani VG. Goserelin 3-month depot shows non-inferiority[...]

By sjmartinez • March 7, 2025

Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis

Swain SM, Macharia H, Cortes J, Dang C, Gianni L, Hurvitz SA, Jackisch C, Schneeweiss A, Slamon D, Valagussa P, du Toit Y, Heinzmann D,[...]

By sjmartinez • October 28, 2022